Printer giant Seiko Epson has won its cross-appeal against cartridge reseller Calidad in a Full Federal Court decision that further clarifies the extent to which patentees can prevent those acquiring a patent’s title from repurposing or manipulating the original product.
Casino and mobile game giant Aristocrat Technologies has sued rival Ainsworth Game Technology for alleged copyright infringement and breaches of Australian consumer law following the suspected theft of trade secrets by an employee.
The Australian Competition & Consumer Commission has commenced legal action against Samsung Electronics for allegedly making false, misleading and deceptive representations when marketing the water resistant capabilities of its Galaxy smartphones.
The contractor behind the Ichthys LNG project has won court approval to use documents discovered in its lawsuit against Dutch paint manufacturer AkzoNobel for use in any potential dispute with INPEX, the head company behind the liquid natural gas project.
APRA has been accused of harbouring an “unhinged hatred” for former IOOF managing director Chris Kelaher by his counsel, who was objecting to internal APRA documents he claims were disparaging of the wealth management company and its executives.
Westpac unit BankSA has reached an agreement to settle a class action alleging it failed to detect the fraud of convicted Ponzi schemer Michael Samra.
A judge overseeing competing consumer class actions against AMP over superannuation fees said he would be “reluctant” to hold a contest between the two cases, as the applicants in the rival proceedings tell the court they are in talks about possible consolidation.
Country Care Group has criticised the DPP for the “argumentative” tone of the notice setting out its criminal cartel case against the mobility equipment provider, and has secured an order for further clarity from prosecutors.
Sparke Helmore has refuted allegations by IOOF subsidiary Australian Executor Trustees (SA) that it failed to provide proper legal advice to the trustee on a 2012 pine plantation sale that left 4,500 investors without millions of dollars worth of assets.
Novartis has applied to amend its proposed patent for an oral form of multiple sclerosis drug Gilenya, as it appeals an invalidity ruling by IP Australia for lack of inventive step.